208 related articles for article (PubMed ID: 26226845)
21. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.
Wachtel M; Dettling M; Koscielniak E; Stegmaier S; Treuner J; Simon-Klingenstein K; Bühlmann P; Niggli FK; Schäfer BW
Cancer Res; 2004 Aug; 64(16):5539-45. PubMed ID: 15313887
[TBL] [Abstract][Full Text] [Related]
22. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
[TBL] [Abstract][Full Text] [Related]
23. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
[TBL] [Abstract][Full Text] [Related]
24. OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma.
Raghavan SS; Mooney KL; Folpe AL; Charville GW
Hum Pathol; 2019 Sep; 91():77-85. PubMed ID: 31299267
[TBL] [Abstract][Full Text] [Related]
25. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
[TBL] [Abstract][Full Text] [Related]
26.
Kendall GC; Watson S; Xu L; LaVigne CA; Murchison W; Rakheja D; Skapek SX; Tirode F; Delattre O; Amatruda JF
Elife; 2018 Jun; 7():. PubMed ID: 29869612
[TBL] [Abstract][Full Text] [Related]
27. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
[TBL] [Abstract][Full Text] [Related]
29. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
30. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
31. [Detection of PAX3/PAX7-FKHR fusion transcript in rhabdomyosarcoma by one-step RT-PCR].
Chang B; Yin BM; Li F; Li XX; Lu TC; Hu WH; Jiang JF; Shi DR
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1336-8. PubMed ID: 12930690
[TBL] [Abstract][Full Text] [Related]
32. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells.
Yoshida H; Miyachi M; Sakamoto K; Ouchi K; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Imamura T; Iehara T; Kakazu N; Hojo H; Hosoi H
Oncogene; 2014 Dec; 33(49):5601-8. PubMed ID: 24213582
[TBL] [Abstract][Full Text] [Related]
33. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
Crose LE; Galindo KA; Kephart JG; Chen C; Fitamant J; Bardeesy N; Bentley RC; Galindo RL; Chi JT; Linardic CM
J Clin Invest; 2014 Jan; 124(1):285-96. PubMed ID: 24334454
[TBL] [Abstract][Full Text] [Related]
34. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
[TBL] [Abstract][Full Text] [Related]
35. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
36. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
37. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
[TBL] [Abstract][Full Text] [Related]
38. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
39. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Missiaglia E; Selfe J; Hamdi M; Williamson D; Schaaf G; Fang C; Koster J; Summersgill B; Messahel B; Versteeg R; Pritchard-Jones K; Kool M; Shipley J
Genes Chromosomes Cancer; 2009 Jun; 48(6):455-67. PubMed ID: 19235922
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Shern JF; Chen L; Chmielecki J; Wei JS; Patidar R; Rosenberg M; Ambrogio L; Auclair D; Wang J; Song YK; Tolman C; Hurd L; Liao H; Zhang S; Bogen D; Brohl AS; Sindiri S; Catchpoole D; Badgett T; Getz G; Mora J; Anderson JR; Skapek SX; Barr FG; Meyerson M; Hawkins DS; Khan J
Cancer Discov; 2014 Feb; 4(2):216-31. PubMed ID: 24436047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
